Cognitive function in health and disease: The role of epigenetic mechanisms

Neurodegenerative Diseases

Volumn 10, Issue 1-4, 2012, Pages 191-194

  Mungenast, Alison E ^a   Tsai, Li Huei ^a,b,c  

^a The Picower Institute for Learning and Memory   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Chromatin; Epigenetics; Histone deacetylase; Learning and memory; Synaptic plasticity

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BUTYRIC ACID; CYCLIN DEPENDENT KINASE 5; GREEN FLUORESCENT PROTEIN; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE 2; PROTEIN C FOS; PROTEIN P25;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; DISEASE ASSOCIATION; ENZYME ACTIVITY; EPIGENETICS; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; LEARNING; MEMORY; MEMORY DISORDER; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; COGNITION DISORDERS; CYCLIN-DEPENDENT KINASE 5; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; MICE; MICE, TRANSGENIC; MODELS, MOLECULAR; MUTATION; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES;

EID: 84860217457     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000334602     Document Type: Article

References (40)

1. Kazantsev AG, Thompson LM: Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008; 7: 854-868.
2. Levenson JM, O'Riordan KJ, Brown KD, et al: Regulation of histone acetylation during memory formation in the hippocampus. J Biol Chem 2004; 279: 40545-40559.
3. Pittenger C, Kandel ER: In search of general mechanisms for long-lasting plasticity: aplysia and the hippocampus. Philos Trans R Soc B Biol Sci 2003; 358: 757-763.
4. Guan JS, Haggarty SJ, Giacometti E, et al: HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009; 459: 55-60.
5. Brownell JE, Allis CD: Special HATs for special occasions: linking histone acetylation to chromatin assembly and gene activation. Curr Opin Genet Dev 1996; 6: 176-184.
6. Bird A: Perceptions of epigenetics. Nature 2007; 447: 396-398.
7. Berger SL, Kouzarides T, Shiekhattar R, et al: An operational definition of epigenetics. Genes Dev 2009; 23: 781-783.
8. De Ruijter AJ, van Gennip AH, Caron HN, et al: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370: 737-749.
9. Peleg S, Sananbenesi F, Zovoilis A, et al: Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 2010; 328: 753-756.
10. Salisbury CM, Cravatt BF: Activity-based probes for proteomic profiling of histone deacetylase complexes. Proc Natl Acad Sci USA 2007; 104: 1171-1176.
11. Baumann K: Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett 1993; 336: 417-424.
12. Paudel HK, Lew J, Ali Z, et al: Brain prolinedirected protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments. J Biol Chem 1993; 268: 23512-23518.
13. Augustinack JC, Sanders JL, Tsai L, et al: Colocalization and fluorescence resonance energy transfer between cdk5 and AT8 suggests a close association in pre-neurofibrillary tangles and neurofibrillary tangles. J Neuropathol Exp Neurol 2002; 61: 557-564.
14. Pei JJ, Grundke-Iqbal I, Iqbal K, et al: Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res 1998; 797: 267-277.
15. Tsai LH, Delalle I, Caviness VS, et al: p35 is a neural-specific regulatory subunit of cyclindependent kinase 5. Nature 1994; 371: 419-423.
16. Ko J, Humbert S, Bronson RT, et al: p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J Neurosci 2001; 21: 6758-6771.
17. Patrick GN, Zukerberg L, Nikolic M, et al: Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999; 402: 615-622.
18. Tseng HC, Zhou Y, Shen Y, et al: A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains. FEBS Lett 2002; 523: 58-62.
19. Mungenast AE, Tsai LH: Addressing the complex etiology of Alzheimer's disease: the role of p25/Cdk5. Future Neurol 2011; 6: 481-496.
20. Lee MS, Kwon YT, Li M, et al: Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000; 405: 360-364.
21. Nguyen MD, Lariviere RC, Julien JP: Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron 2001; 30: 135-147.
22. Smith PD, Crocker SJ, Jackson-Lewis V, et al: Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2003; 100: 13650-13655.
23. Paoletti P, Vila I, Rife M, et al: Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5. J Neurosci 2008; 28: 10090-10101.
24. Sen A, Thom M, Martinian L, et al: Deregulation of cdk5 in hippocampal sclerosis. J Neuropathol Exp Neurol 2006; 65: 55-66.
25. Cruz JC, Tseng HC, Goldman JA, et al: Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 2003; 40: 471-483.
26. Fischer A, Sananbenesi F, Pang PT, et al: Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron 2005; 48: 825-838.
27. Fischer A, Sananbenesi F, Wang X, et al: Recovery of learning and memory is associated with chromatin remodelling. Nature 2007; 447: 178-182.
28. Kilgore M, Miller CA, Fass DM, et al: Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2009; 35: 870-880.
29. Ricobaraza A, Cuadrado-Tejedor M, Perez- Mediavilla A, et al: Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 2009; 34: 1721-1732.
30. Chuang DM, Leng Y, Marinova Z, et al: Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 2009; 32: 591-601.
31. Mai A, Rotili D, Valente S, et al: Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. Curr Pharm Des 2009; 15: 3940-3957.
32. Selvi BR, Cassel JC, Kundu TK, et al: Tuning acetylation levels with HAT activators: therapeutic strategy in neurodegenerative diseases. Biochim Biophys Acta 2010; 1799: 840-853.
33. Gauthier S, Aisen PS, Ferris SH, et al: Effect of tramiprosate in patients with mild-tomoderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging 2009; 13: 550-557.
34. Saumier D, Duong A, Haine D, et al: Domain- specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase study. J Nutr Health Aging 2009; 13: 808-812.
35. Holmes C, Boche D, Wilkinson D, et al: Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216-223.
36. Patton RL, Kalback WM, Esh CL, et al: Amyloid- beta peptide remnants in AN-1792- immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 2006; 169: 1048-1063.
37. Talan J: High-dose bapineuzumab puts some AD patients at risk for vasogenic cerebral edema: those taking largest dose removed from trials. Neurol Today 2009; 9: 4.
38. Alzheimer's Disease International. World Alzheimer report 2010: the global economic impact of dementia. London, Alzheimer's Disease International: The International Federation of Alzheimer's Disease and Related Disorders Societies, 2010.
39. Alzheimer's Disease International. World Alzheimer report 2009: the global economic impact of dementia. London, Alzheimer's Disease International: The International Federation of Alzheimer's Disease and Related Disorders Societies, 2009.
40. Hardy J: A hundred years of Alzheimer's disease research. Neuron 2006; 52: 3-13.